External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>Axis New Year Picks: We are proud to announce our exclusive report: Axis New Year Picks 2023 – Focus on 6 Golden Themes.</li><li>The report contains deeply-researched 9 stocks that are best-placed to deliver excellent performance in 2023 and thereby strengthen your investment portfolio.</li><li>Axis Alpha: Axis Alpha reported an excellent monthly strike rate of 78% in Dec’22. It continued to deliver robust returns with absolute profits of over 5.4 Lc since its inception in May’20.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Axis New Year Picks: We are proud to announce our exclusive report: Axis New Year Picks 2023 – Focus on 6 Golden Themes.The report contains deeply-researched 9 stocks that are best-placed to deliver excellent performance in 2023 and thereby strengthen your investment portfolio.Axis Alpha: Axis Alpha reported an excellent monthly strike rate of 78% in Dec’22. It continued to deliver robust returns with absolute profits of over 5.4 Lc since its inception in May’20.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Equity Bottom-Up

Solara Active Pharma Sciences / Equity Bottom-Up

<div><ul><li>Merger with Aurore has been cancelled - <span style="font-size: var(--content-font-size);">The company’s board has decided not to go ahead with the proposed merger with Aurore and instead intends to continue focusing on its core competency and organic growth.</span></li></ul><div><ul><li>Debt levels rise due to working capital loans - <span style="font-size: var(--content-font-size);">The company’s Net Debt to EBITDA ratio stands at ~10x in FY22. It increased to Rs 9,27 Cr in FY22 from Rs 4,08 Cr in FY21, primarily due to 1.) </span><span style="font-size: var(--content-font-size);">Fresh Term loan to support Capex across the locations 2.) Increased inventory build-up planned for Covid-19 related business 3.) Increase in KSMs and raw material inventories to offset the current market volatility.</span></li></ul><div><div><div><div><ul><li>However, the company is taking actions to structurally optimize inventory and right-size the working capital underway.</li></ul></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Merger with Aurore has been cancelled - The company’s board has decided not to go ahead with the proposed merger with Aurore and instead intends to continue focusing on its core competency and organic growth.Debt levels rise due to working capital loans - The company’s Net Debt to EBITDA ratio stands at ~10x in FY22. It increased to Rs 9,27 Cr in FY22 from Rs 4,08 Cr in FY21, primarily due to 1.) Fresh Term loan to support Capex across the locations 2.) Increased inventory build-up planned for Covid-19 related business 3.) Increase in KSMs and raw material inventories to offset the current market volatility.However, the company is taking actions to structurally optimize inventory and right-size the working capital underway.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Result Update - Solara Active Pharma Sciences Ltd

<p>We expect Gross Margins to be impacted due to an increase in revenue share from non-regulated markets and an increase in raw material prices going onwards. Hence, we recommend a HOLD rating on the stock with a target price of INR 1,670 (PE 20x for FY23EPS).</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We expect Gross Margins to be impacted due to an increase in revenue share from non-regulated markets and an increase in raw material prices going onwards. Hence, we recommend a HOLD rating on the stock with a target price of INR 1,670 (PE 20x for FY23EPS).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Solara Active Pharma Sciences: Gross Margins Impacted

India

Solara Active Pharma Sciences Limited manufactures pharmaceutical products. The Company focuses on production, processing, formulating, merchandising, distributing, and trading of active pharmaceutical ingredients. Solara Active Pharma Sciences serves patients in India.

Solara Active Pharma Sciences (SOLARA IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Solara Active Pharma Sciences (SOLARA IN)

Axis Research Scorecard Report - Dec 22

Axis New Year Picks: We are proud to announce our exclusive report: Axis New Year Picks 2023 – Focus on 6 Golden Themes.

Axis Direct

Result Update - Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences (Solara) reported subdued performance in Q4FY22 with revenue at Rs 361 Cr, registering notable de-growth of 18.8% YoY

Axis Direct

Solara Active Pharma Sciences: Gross Margins Impacted

We expect Gross Margins to be impacted due to an increase in revenue share from non-regulated markets and an increase in raw material prices going...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)